Pharmacological characterization of the novel γ-secretase modulator AS2715348, a potential therapy for Alzheimer's disease, in rodents and nonhuman primates

Neuropharmacology

Volumn 79, Issue , 2014, Pages 412-419

  Mitani, Yasuyuki ^a   Akashiba, Hiroki ^a   Saita, Kyoko ^a   Yarimizu, Junko ^a   Uchino, Hiroshi ^a   Okabe, Mayuko ^a   Asai, Makoto ^a   Yamasaki, Shingo ^a   Nozawa, Takashi ^a   Ishikawa, Noritoshi ^a   Shitaka, Yoshitsugu ^a   Ni, Keni ^a   Matsuoka, Nobuya ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Secretase; Alzheimer's disease; Amyloid ; Cognition

Indexed keywords

[3 [(CYCLOHEXYLMETHYL)(3,3 DIMETHYLBUTYL)AMINO] 2 [4 (TRIFLUOROMETHYL)PHENYL]CYCLOHEXYL]ACETIC ACID; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; AS 2715348; CYCLOHEXYLAMINE DERIVATIVE; NOTCH RECEPTOR; UNCLASSIFIED DRUG; 3-((CYCLOHEXYLMETHYL)(3,3-DIMETHYLBUTYL)AMINO)-2-(4-(TRIFLUOROMETHYL)PHENYL)CYCLOHEXYL)ACETIC ACID; ACETIC ACID DERIVATIVE; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-38); AMYLOID BETA-PROTEIN (1-42); APP PROTEIN, HUMAN; NEUROPROTECTIVE AGENT; NOOTROPIC AGENT; PEPTIDE FRAGMENT; SECRETASE;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG EFFICACY; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; MACACA FASCICULARIS; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TRANSGENIC MOUSE; ANIMAL; BRAIN; CHEMICAL STRUCTURE; CHEMISTRY; COGNITION; DISEASE MODEL; DRUG EFFECTS; GENETICS; METABOLISM; SPRAGUE DAWLEY RAT; TUMOR CELL LINE;

ACETATES; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; BRAIN; CELL LINE, TUMOR; COGNITION; CYCLOHEXYLAMINES; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MACACA FASCICULARIS; MALE; MICE; MICE, TRANSGENIC; MOLECULAR STRUCTURE; NEUROPROTECTIVE AGENTS; NOOTROPIC AGENTS; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NOTCH;

EID: 84891809505     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2013.12.013     Document Type: Article

References (30)

1. D. Beher, E.E. Clarke, J.D. Wrigley, A.C. Martin, A. Nadin, I. Churcher, and M.S. Shearman Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma-secretase at a novel site. Evidence for an allosteric mechanism J. Biol. Chem. 279 2004 43419 43426
2. C.R. Burton, J.E. Meredith, D.M. Barten, M.E. Goldstein, C.M. Krause, C.J. Kieras, L. Sisk, L.G. Iben, C. Polson, M.W. Thompson, X.A. Lin, J. Corsa, T. Fiedler, M. Pierdomenico, Y. Cao, A.H. Roach, J.L. Cantone, M.J. Ford, D.M. Drexler, R.E. Olson, M.G. Yang, C.P. Bergstrom, K.E. McElhone, J.J. Bronson, J.E. Macor, Y. Blat, R.H. Grafstrom, A.M. Stern, D.A. Seiffert, R. Zaczek, C.F. Albright, and J.H. Toyn The amyloid-beta rise and gamma-secretase inhibitor potency depend on the level of substrate expression J. Biol. Chem. 283 2008 22992 23003
3. J.J. Cook, K.R. Wildsmith, D.B. Gilberto, M.A. Holahan, G.G. Kinney, P.D. Mathers, M.S. Michener, E.A. Price, M.S. Shearman, A.J. Simon, J.X. Wang, G. Wu, K.E. Yarasheski, and R.J. Bateman Acute gamma-secretase inhibition of nonhuman primate CNS shifts amyloid precursor protein (APP) metabolism from amyloid-beta production to alternative APP fragments without amyloid-beta rebound J. Neurosci. 30 2010 6743 6750
4. V. Coric, C.H. van Dyck, S. Salloway, N. Andreasen, M. Brody, R.W. Richter, H. Soininen, S. Thein, T. Shiovitz, G. Pilcher, S. Colby, L. Rollin, R. Dockens, C. Pachai, E. Portelius, U. Andreasson, K. Blennow, H. Soares, C. Albright, H.H. Feldman, and R.M. Berman Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease Arch. Neurol. 69 2012 1430 1440
5. B. De Strooper, P. Saftig, K. Craessaerts, H. Vanderstichele, G. Guhde, W. Annaert, K. Von Figura, and F. Van Leuven Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein Nature 391 1998 387 390
6. R.S. Doody, R. Raman, M. Farlow, T. Iwatsubo, B. Vellas, S. Joffe, K. Kieburtz, F. He, X. Sun, R.G. Thomas, P.S. Aisen, E. Siemers, G. Sethuraman, and R. Mohs A phase 3 trial of semagacestat for treatment of Alzheimer's disease N. Engl. J. Med. 369 2013 341 350
7. J.L. Eriksen, S.A. Sagi, T.E. Smith, S. Weggen, P. Das, D.C. McLendon, V.V. Ozols, K.W. Jessing, K.H. Zavitz, E.H. Koo, and T.E. Golde NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo J. Clin. Investig. 112 2003 440 449
8. A.S. Fleisher, R. Raman, E.R. Siemers, L. Becerra, C.M. Clark, R.A. Dean, M.R. Farlow, J.E. Galvin, E.R. Peskind, J.F. Quinn, A. Sherzai, B.B. Sowell, P.S. Aisen, and L.J. Thal Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease Arch. Neurol. 65 2008 1031 1038
9. R.C. Green, L.S. Schneider, D.A. Amato, A.P. Beelen, G. Wilcock, E.A. Swabb, and K.H. Zavitz Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial JAMA 302 2009 2557 2564
10. A. Hall, R.L. Elliott, G.M.P. Giblin, I. Hussain, J. Musgrave, A. Naylor, R. Sasse, and B. Smith Piperidine-derived γ-secretase modulators Bioorg. Med. Chem. Lett. 20 2010 1306 1311
11. K. Hsiao, P. Chapman, S. Nilsen, C. Eckman, Y. Harigaya, S. Younkin, F. Yang, and G. Cole Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice Science 274 1996 99 103
12. M.Z. Kounnas, A.M. Danks, S. Cheng, C. Tyree, E. Ackerman, X. Zhang, K. Ahn, P. Nguyen, D. Comer, L. Mao, C. Yu, D. Pleynet, P.J. Digregorio, G. Velicelebi, K.A. Stauderman, W.T. Comer, W.C. Mobley, Y.-M. Li, S.S. Sisodia, R.E. Tanzi, and S.L. Wagner Modulation of γ-secretase reduces β-amyloid deposition in a transgenic mouse model of Alzheimer's disease Neuron 67 2010 769 780
13. T.A. Lanz, G.J. Fici, and K.M. Merchant Lack of specific amyloid-beta(1-42) suppression by nonsteroidal anti-inflammatory drugs in young, plaque-free Tg2576 mice and in guinea pig neuronal cultures J. Pharmacol. Exp. Ther. 312 2005 399 406
14. T. Li, H. Wen, C. Brayton, F.M. Laird, G. Ma, S. Peng, L. Placanica, T.C. Wu, B.J. Crain, D.L. Price, C.G. Eberhart, and P.C. Wong Moderate reduction of gamma-secretase attenuates amyloid burden and limits mechanism-based liabilities J. Neurosci. 27 2007 10849 10859
15. L.F. Lue, Y.M. Kuo, A.E. Roher, L. Brachova, Y. Shen, L. Sue, T. Beach, J.H. Kurth, R.E. Rydel, and J. Rogers Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer's disease Am. J. Pathol. 155 1999 853 862
16. R.L. Martone, H. Zhou, K. Atchison, T. Comery, J.Z. Xu, X. Huang, X. Gong, M. Jin, A. Kreft, B. Harrison, S.C. Mayer, S. Aschmies, C. Gonzales, M.M. Zaleska, D.R. Riddell, E. Wagner, P. Lu, S.C. Sun, J. Sonnenberg-Reines, A. Oganesian, K. Adkins, M.W. Leach, D.W. Clarke, D. Huryn, M. Abou-Gharbia, R. Magolda, J. Bard, G. Frick, S. Raje, S.B. Forlow, C. Balliet, M.E. Burczynski, P.H. Reinhart, H.I. Wan, M.N. Pangalos, and J.S. Jacobsen Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein γ-secretase for the treatment of Alzheimer's disease J. Pharmacol. Exp. Ther. 331 2009 598 608
17. J.M. McDonald, G.M. Savva, C. Brayne, A.T. Welzel, G. Forster, G.M. Shankar, D.J. Selkoe, P.G. Ince, and D.M. Walsh The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia Brain 133 2010 1328 1341
18. C.A. McLean, R.A. Cherny, F.W. Fraser, S.J. Fuller, M.J. Smith, K. Beyreuther, A.I. Bush, and C.L. Masters Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease Ann. Neurol. 46 1999 860 866
19. J. Milano, J. McKay, C. Dagenais, L. Foster-Brown, F. Pognan, R. Gadient, R.T. Jacobs, A. Zacco, B. Greenberg, and P.J. Ciaccio Modulation of notch processing by γ-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation Toxicol. Sci. 82 2004 341 358
20. Y. Mitani, J. Yarimizu, H. Akashiba, Y. Shitaka, K. Ni, and N. Matsuoka Amelioration of cognitive deficits in plaque-bearing Alzheimer's disease model mice through selective reduction of nascent soluble Aβ42 without affecting other Aβ pools J. Neurochem. 125 2013 465 472
21. Y. Mitani, J. Yarimizu, K. Saita, H. Uchino, H. Akashiba, Y. Shitaka, K. Ni, and N. Matsuoka Differential effects between γ-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice J. Neurosci. 32 2012 2037 2050
22. Y. Ohki, T. Higo, K. Uemura, N. Shimada, S. Osawa, O. Berezovska, S. Yokoshima, T. Fukuyama, T. Tomita, and T. Iwatsubo Phenylpiperidine-type γ-secretase modulators target the transmembrane domain 1 of presenilin 1 EMBO J. 30 2011 4815 4824
23. Y. Qi, M. Morishima-Kawashima, T. Sato, R. Mitsumori, and Y. Ihara Distinct mechanisms by mutant presenilin 1 and 2 leading to increased intracellular levels of amyloid beta-protein 42 in Chinese hamster ovary cells Biochemistry 42 2003 1042 1052
24. T. Saito, T. Suemoto, N. Brouwers, K. Sleegers, S. Funamoto, N. Mihira, Y. Matsuba, K. Yamada, P. Nilsson, J. Takano, M. Nishimura, N. Iwata, C. Van Broeckhoven, Y. Ihara, and T.C. Saido Potent amyloidogenicity and pathogenicity of Abeta43 Nat. Neurosci. 14 2011 1023 1032
25. Y. Takahashi, I. Hayashi, Y. Tominari, K. Rikimaru, Y. Morohashi, T. Kan, H. Natsugari, T. Fukuyama, T. Tomita, and T. Iwatsubo Sulindac sulfide is a noncompetitive gamma-secretase inhibitor that preferentially reduces Abeta 42 generation J. Biol. Chem. 278 2003 18664 18670
26. B. Van Broeck, J.M. Chen, G. Tréton, M. Desmidt, C. Hopf, N. Ramsden, E. Karran, M. Mercken, and A. Rowley Chronic treatment with a novel γ-secretase modulator, JNJ-40418677, inhibits amyloid plaque formation in a mouse model of Alzheimer's disease Br. J. Pharmacol. 163 2011 375 389
27. S. Weggen, J.L. Eriksen, P. Das, S.A. Sagi, R. Wang, C.U. Pietrzik, K.A. Findlay, T.E. Smith, M.P. Murphy, T. Bulter, D.E. Kang, N. Marquez-Sterling, T.E. Golde, and E.H. Koo A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity Nature 414 2001 212 216
28. S. Weggen, J.L. Eriksen, S.A. Sagi, C.U. Pietrzik, T.E. Golde, and E.H. Koo Aβ42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain J. Biol. Chem. 278 2003 30748 30754
29. M.S. Wolfe, W. Xia, B.L. Ostaszewski, T.S. Diehl, W.T. Kimberly, and D.J. Selkoe Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity Nature 398 1999 513 517
30. G.T. Wong, D. Manfra, F.M. Poulet, Q. Zhang, H. Josien, T. Bara, L. Engstrom, M. Pinzon-Ortiz, J.S. Fine, H.-J.J. Lee, L. Zhang, G.A. Higgins, and E.M. Parker Chronic treatment with the γ-secretase inhibitor LY-411,575 inhibits β-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation J. Biol. Chem. 279 2004 12876 12882